Drug Trial Radar · NCT01950247
Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron
Last checked: Nov 20, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,025
Actual
Start
Aug 15, 2013
Primary completion
May 20, 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- American Regent, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to compare the safety, effect on quality of life, and resource utilization of Injectafer vs. intravenous (IV) iron standard of care (SOC) for the treatment of iron deficiency anemia (IDA) in an infusion center setting. The study will also assess the ability of baseline serum hepcidin levels to predict if subjects will have a clinically meaningful hemoglobin response to oral iron therapy or to IV iron therapy.
Conditions
- Iron Deficiency Anemia (IDA)
Interventions
InjectaferDrug
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
SOCDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Multidimensional Assessment of Fatigue (MAF) ScoresTime frame: Baseline to Day 30
- Work Productivity and Activity Impairment Questionnaire (WPAI) ScoresTime frame: Baseline and Day 30
- Treatment Satisfaction Questionnaire for Medication Version 1.4 ScoresTime frame: Baseline and Day 30
- Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.Time frame: Baseline and Day 30
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.